Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICA-17043 in sickle cell disease
NCT00102791Phase 3Terminated
- Sponsor
- Icagen
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of senicapoc in sickle cell disease (SCD), sponsored by Icagen. Started Feb 2005; status: terminated.
02
Drugs
senicapoc
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT00102791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00102791.